Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Studies for Newly Diagnosed Lung Cancer

 

Onartuzumab (MetMAb) for Squamous Non-Small Cell Lung Cancer (UW11048)
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Gemcitabine + Cisplatin or Carboplatin as First-line Treatment for Patients With Stage IIIb or IV Squamous Non-small Cell Lung Cancer (NSCLC)

Investigator: Keith D. Eaton, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01519804

Safety and Tolerability of Nivolumab (BMS-936558) for Non-small Cell Lung Cancer (UW11037)
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab maintenance, Erlotinib, Ipilimumab or monotherapy in First line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

Investigator: Laura Q.M. Chow, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01454102

Onartuzumab (MetMAb) + Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer (UW11049)
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC

Investigator: Keith D. Eaton, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01496742